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Drug-resistant Plasmodium falciparum malaria is a major public health problem. An elevated pfmdr1 gene copy number (CN) is
known to decrease parasite sensitivity to the commonly used antimalarial mefloquine (MFQ). To understand the relationship
between pfmdr1 CN and mefloquine resistance, we evaluated pfmdr1 transcript levels in three P. falciparum strains with differ-
ent CNs in the presence and absence of MFQ. Parasite strains with multiple pfmdr1 gene copies exhibited higher relative tran-
script levels than single-copy parasites, and MFQ induced pfmdr1 expression above the levels without treatment in all three
strains evaluated. Concomitant morphology analyses of the sampled cultures revealed that MFQ treatment of synchronized
ring-stage parasites induced a delay in parasite maturation through the intraerythrocytic cycle. pfmdr1 expression peaks in the
ring stage, and MFQ could be causing increased transcription by delaying parasite maturation. However, pretreatment with
mefloquine did not affect the artemisinin in vitro half-maximal inhibitory concentration (IC50). These results suggest that MFQ-
induced increases in pfmdr1 expression are the direct result of the maturation delay at the ring stage but that this change in ex-
pression does not affect the antimalarial activity of artemisinin.
With 225 million estimated clinical infections that result in781,000 deaths annually, the protozoan Plasmodium falcip-
arum causes the most severe form of malaria (1). Efforts to control
malaria have been hampered by the development of resistance to
antimalarials such as chloroquine (CQ), sulfadoxine-pyrimeth-
amine, and mefloquine (MFQ). Artemisinin-based combination
therapies (ACT) are now the first-line treatment for P. falciparum
malaria. Unfortunately, resistance to these new drugs is believed
to be developing, based on the observation of slower in vivo par-
asite clearance times (2–4). The molecular basis for resistance is
unclear; thus, a better understanding of the ACT resistance mech-
anism is needed.
Early investigations into antimalarial resistance led to the iden-
tification of a malaria homolog to the mammalian multidrug re-
sistance gene (5–7). The P. falciparum multidrug resistance gene
(pfmdr1) encodes an ATP-binding cassette protein called P-glyco-
protein homolog 1 (Pgh1), which is located on the parasite food
vacuole membrane (6) and functions as a transporter (8). The
transporter function of Pgh1 couples ATP hydrolysis with solute
import into the food vacuole (9). The pfmdr1 gene has been iden-
tified as a possible modulator of resistance to a number of antima-
larials (10), and the Pgh1 protein has also been implicated as a
specific target of antimalarial drugs, such as MFQ (11). Substan-
tial data support a relationship between the pfmdr1 gene and MFQ
resistance both in vitro and in vivo (12–21). Specifically, an abun-
dance of in vitro and clinical data link higher pfmdr1 gene copy
number and expression with reduced parasite susceptibility to
drugs such as quinine (QN), MFQ, and, more recently, artemis-
inin (9, 12, 13, 16, 20–28).
The control of pfmdr1 gene expression is only partially under-
stood. MFQ-resistant field isolates with higher pfmdr1 copy num-
bers overexpress the transcript compared to isolates with a single
copy of pfmdr1 (8, 29), indicating a direct correlation where the
presence of more gene copies results in higher constitutive expres-
sion. Expression may also be inducible; a recent study demon-
strated higher pfmdr1 transcript levels in a strain bearing a single
pfmdr1 gene copy after treatment with CQ, MFQ, and QN (30).
This suggests that exposure to quinoline drugs can induce pfmdr1
expression and thereby possibly augment resistance to antimalar-
ials such as artemisinin and its derivatives. This is of particular
importance because artesunate-mefloquine is a common ACT. In
this study, we sought to expand on these observations to better
understand the mechanism of pfmdr1 induction and how this
might affect parasite sensitivity to artemisinins.
MATERIALS AND METHODS
Parasite cultivation. We used P. falciparum cultures of three clonal par-
asite lines obtained from the Malaria Research and Reference Reagent
Resource Center (MR4) (Manassas, VA): (i) 3D7, which has one pfmdr1
copy and is sensitive to CQ and MFQ; (ii) FCB, which has 2 copies and is
CQ resistant and MFQ sensitive; and (iii) Dd2, which has 4 pfmdr1 copies
and is resistant to CQ and MFQ. Parasite cultures were maintained at
37°C using the standard Trager-Jenson method for malaria parasite cul-
ture (31). Pooled human type O serum at 10% and red blood cells
(Research Blood Components, LLC, Boston, MA) at 2% hematocrit were
used for all cultures and experimental conditions. Cultures were synchro-
nized with 5% sorbitol solution every 48 h for three consecutive life cycles
to obtain a uniform culture of parasites at a single stage (32).
Gene expression analysis. Sorbitol-synchronized ring-stage parasites
were exposed to 100 ng/ml MFQ for 48 h. Total RNA was isolated from
cultures at 0, 6, 12, 24, and 48 h after addition of drug using TriReagent
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(Molecular Research Center, Inc., Cincinnati, OH), according to the
manufacturer’s instructions. Real-time reverse transcriptase PCR (RT-
PCR) was employed to assess relative pfmdr1 (the reference identification
number for pfmdr1 from the Plasmodium Genomics Database [Plas-
moDB] is PFE1150w) mRNA levels between parasite lineages using the
CT analysis, as previously described (33). The threshold cycle (CT)
value represents the PCR cycle at which DNA amplification crosses the
threshold value. The CT for each sample is defined as CTpfmdr1  CTpfldh.
Differences in pfmdr1 gene expression for untreated cultures were com-
pared to expression from single-copy 3D7 untreated cultures. Differences
in pfmdr1 expression for mefloquine-treated cultures were compared to
the corresponding untreated culture of the same strain. In experiments
involving drug exposure, untreated cultures were used as the negative
control, and atovaquone (ATQ) (1 M)-treated cultures were used to
control for effects on gene expression due to the addition to the culture
medium of a drug with a known site of action distinct from the pfmdr1-
encoded protein. Expression of the developmentally regulated trophozo-
ite antigen R45-like gene (PlasmoDB no. PFD1175w) (tar45-like gene),
which is transcribed during the ring stage only, was assessed using a SYBR
green assay as previously described (34). The single-copy P. falciparum
lactate dehydrogenase gene (PlasmoDB no. PF13-0141), pfldh, was used
as the reference gene for analysis.
The primers and fluorescent probes for pfmdr1 were designed using
ABI’s Primer Express software and are as follows (5= to 3=): (i) pfmdr1
forward primer, TGCCCACAGAATTGCATCTATAA; (ii) pfmdr1 re-
verse primer, GACTGTACAAAGGTTCCATTTCGA; and (iii) pfmdr1
probe, 6-carboxyfluorescein (FAM)-ACGATCAGACAAAATT-MGB.
The published primers and fluorescent probes for the pfldh and tar45-like
genes (34) were as follows (5= to 3=): (i) pfldh forward primer, ACGATT
TGGCTGGAGCAGAT; (ii) pfldh reverse primer, TCTCTATTCCATTCT
TTGTCACTCTTTC; (iii) pfldh probe, FAM-AGTAATAGTAACAGCTG
GATTTACCAAGGCCCCA-6-carboxytetramethylrhodamine (TAMRA);
(iv) tar45-like gene forward primer, ACGAGCTGACCCACCAAA; and
(v) tar45-like gene reverse primer, CATTTAAGTCTGTCTTCATTCTAC
TTCT. Real-time RT-PCR amplifications were performed in a 96-well
plate in the ABI Prism 7700 sequence detection system in a total volume of
30 l (100 ng RNA plus PCR mixture to reach a total volume of 30 l).
Each real-time RT-PCR amplification was performed in duplicate using a
previously reported method that combines cDNA synthesis and real-time
PCR in one reaction: 30 min at 48°C for the RT reaction and then 10 min
at 94°C, followed by a total of 40 PCR cycles (15 s at 94°C and 1 min at
60°C) (33). During the amplification, the fluorescence of FAM, TAMRA,
and ROX (a passive reference dye) was measured by the 7700 sequence
detector in each well of the 96-well plate. All experiments were conducted
a minimum of 3 times for statistical analysis.
Morphology analysis. Thin blood smears were prepared and stained
with Giemsa stain (Sigma-Aldrich Co., St. Louis, MO) at 0, 6, 12, 24, and
48 h after the addition of MFQ. Parasitemia and parasite morphology
were assessed via light microscopy. Parasitemia was calculated as the
number of parasitized red blood cells per 1,000 total red blood cells. Mor-
phology was examined and the number of parasites at each asexual blood
stage was assessed for a minimum of 100 parasites. Parasite morphologies
were classified as follows: (i) parasites with a single nucleus and charac-
teristic ring appearance were classified as rings, (ii) parasites containing a
single nucleus and hemozoin were considered trophozoites, and (iii)
multinucleated parasites with ample hemozoin represented schizonts.
IC50 determinations. Parasite drug susceptibility was determined us-
ing a modification of a published SYBR green I flow cytometry assay (35).
The drug concentration required to inhibit 50% of parasite growth (IC50)
was calculated using the sigmoidal dose-response nonlinear regression
equation in GraphPad Prism software.
Statistical analysis. Each experiment was conducted a minimum of
three times for statistical analysis. All statistical analyses were conducted
on the raw data (CT) for each condition using JMP software (SAS Insti-
tute, Inc., Cary, NC). Tukey’s test was used to determine significant dif-
ferences at a P value of 0.05 between the parasite strains because signif-
icance is determined for all possible pairwise comparisons of the three
strains. Student’s t test was used to determine significant differences at a P
value of 0.05 between untreated and drug-treated expression levels.
RESULTS
pfmdr1 expression is proportional to copy number in untreated
parasites. Synchronized parasites from three clonal strains of P.
falciparum with different pfmdr1 gene copy numbers were cul-
tured for 24 h and sampled at 0, 6, 12, and 24 h. pfmdr1 gene
expression increased proportionally with the number of pfmdr1
gene copies present in the parasite at all time points: Dd2 parasites
(four pfmdr1 gene copies) had 3- to 8-times-higher expression
levels than 3D7 (one copy), while FCB (two copies) had 2- to
3-fold-higher levels of expression than 3D7, (Fig. 1). The differ-
ences between Dd2 and 3D7 are significant (P  0.05) throughout
the 24-hour time period; the difference between FCB and 3D7 was
significant only at the 0 h time point. The results indicate that
FIG 1 Fold differences in pfmdr1 gene expression over time in parasite strains with different pfmdr1 copy numbers. Transcript levels of pfmdr1 relative to the
single-copy P. falciparum lactate dehydrogenase gene were evaluated over time following synchronization using real-time RT-PCR. Fold differences in pfmdr1
expression are relative to 3D7 expression at each time point (not shown), which was set to 1 (black line). Parasite strains with more than one pfmdr1 copy had
higher levels of transcript than single-copy 3D7 parasites. These results were significant for Dd2 through the 24-hour time point. Results are from 6 independent
experiments. Statistics were done on the raw data (CT) at each time point. *, P  0.05 by Tukey’s test.
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there is a direct relationship between pfmdr1 copy number and
expression of the pfmdr1 transcript.
Mefloquine exposure causes increased pfmdr1 gene expres-
sion. Our results show that, compared with pfmdr1 transcript lev-
els in the respective untreated culture for each strain, the exposure
to mefloquine (MFQ) in all three strains tended to upregulate the
expression of pfmdr1, with the increase appearing to be an early
response that occurred within the first 6 h (Fig. 2). Although we
consistently saw higher pfmdr1 expression in MFQ-exposed par-
asites than in untreated parasites of the same strain, these results
were significant only after synchronized rings of 3D7 with one
copy of pfmdr1 (P  0.005) and of Dd2 with four copies of pfmdr1
(P  0.05) were exposed to MFQ for 12 h. Gene expression anal-
ysis of pfmdr1 following parasite exposure to the structurally un-
related antimalarial compound atovaquone (ATQ) yielded no sig-
nificant difference in pfmdr1 transcript levels compared with
those in untreated controls of the same parasite strain (see Fig. S1
in the supplemental material). pfmdr1 upregulation was observed
only after exposure to MFQ not after exposure to ATQ, suggesting
that increased pfmdr1 expression is a specific P. falciparum re-
sponse to MFQ and not a generalized response to antiparasitic
drug treatment. Upregulation of pfmdr1 expression in MFQ-
treated parasites compared to untreated parasites was also ob-
served when MFQ was added to synchronized trophozoite stage
parasites; however, these results were not significant (see Fig. S2 in
the supplemental material).
Mefloquine induces P. falciparum cell cycle delay. Parasite
maturation through the asexual blood stages was evaluated by thin
blood smears using light microscopy. For all 3 strains, untreated
parasite populations progressed from predominantly rings to pre-
dominantly trophozoites over 24 h. In contrast, the addition of
MFQ to synchronized ring-stage parasites delayed parasite matu-
ration at the ring stage (Fig. 3). In all strains tested, the delay in
maturation began at 6 h posttreatment and became more pro-
nounced by the 12-hour time point. This phenotype occurred
following exposure to MFQ only. The addition of ATQ did not
result in the same delay in maturation. Figure 4 shows that when
MFQ was added to cultures containing predominantly synchro-
nized trophozoites, maturation proceeded normally until the ring
stage (24 h), at which point maturation again stalled. Thus, MFQ
appears to have a selective effect on ring-stage parasites.
MFQ treatment results in increased expression of ring-stage
genes. To confirm the effects of MFQ on parasite development, we
measured, in duplicate, the expression of the developmentally reg-
ulated trophozoite antigen R45-like (tar45-like) gene (PlasmoDB
FIG 2 Fold change in pfmdr1 gene expression in parasites with different pfmdr1 copy numbers over time following mefloquine exposure. Fold changes in pfmdr1
expression are relative to that for the corresponding untreated culture for each strain at each time point (not shown), which was set to 1.0 (black line). Significant
increases in pfmdr1 expression upon mefloquine exposure (100 ng/ml) were observed at the 12-hour time point for 3D7 and Dd2 cultures. Results are from 6
independent experiments. Statistics were done on the raw data (CT) at each time point. *, P  0.05; **, P  0.005 (by Student’s t test).
FIG 3 Morphology stage development of untreated and drug-treated ring-
stage parasites. Synchronized ring-stage 3D7 (1 pfmdr1 copy), FCB (2 copies),
and Dd2 (4 copies) parasites that were untreated or treated with atovaquone
(ATQ) (1 M) or mefloquine (MFQ) (100 ng/ml) were monitored over time.
Untreated and ATQ-treated cultures progressed through the normal asexual
cell cycle. MFQ treatment caused a delay in parasite maturation, resulting in a
persistence of ring stages. All strains exhibited this delay.
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no. PFD1175w), which is transcribed during the ring stage only
(34). Compared with tar45-like gene expression in untreated con-
trols of each strain (which was set to 1.00), the fold difference in
tar45-like gene expression relative to that of pfldh was higher for
all three strains at 12 h after MFQ treatment (3D7, 5.73; FCB, 6.14;
Dd2, 6.48). Expression of the tar45-like gene was not affected by
ATQ (3D7, 1.31; FCB, 1.02; Dd2, 1.47). These data confirm that
MFQ-treated parasites remained in the ring stage for a longer
period of time than untreated parasites.
pfmdr1 is expressed primarily during the ring stage of the
intraerythrocytic cycle. Untreated cultures of each parasite strain
were assessed for morphology and pfmdr1 gene expression as de-
scribed above. A direct relationship was observed between the
proportion of ring-stage parasites in the culture and the fold dif-
ference in pfmdr1 transcript levels (Fig. 5). These data suggest that
ring-stage parasites express higher levels of the pfmdr1 transcript
than later stages and that the MFQ-induced increase in pfmdr1
expression could be due to the maturation delay.
MFQ-induced maturation delay has no effect on artesunate
IC50. Because MFQ-treated parasites expressed more pfmdr1, we
tested to see whether MFQ treatment might antagonize its com-
mon partner drug artesunate. Parasites were exposed to MFQ for
12 h to induce the maturation delay. The half-maximal inhibitory
concentration (IC50) of artesunate was assessed with MFQ-ex-
posed parasites. A SYBR green I flow cytometry assay was used to
quantify parasite growth inhibition by artesunate, as previously
reported (35). We found no difference in artesunate IC50 values
between untreated and MFQ-treated parasites (Table 1).
DISCUSSION
The objective of this study was to determine how mefloquine
(MFQ) treatment affects pfmdr1 gene expression in parasites with
different pfmdr1 gene copy numbers. We found that the expres-
sion of pfmdr1 was upregulated following MFQ treatment, and
parasites with four pfmdr1 copies expressed higher transcript lev-
els than single-copy parasites. Interestingly, cultures of MFQ-sen-
sitive FCB parasites (two pfmdr1 gene copies) did not exhibit a
significant increase in pfmdr1 expression following MFQ treat-
ment compared with single-copy 3D7 parasites at any of the time
points assessed. One possible explanation is that there may be a
threshold for the number of pfmdr1 gene copies required for a
parasite to exhibit the MFQ-resistant phenotype. Because these
parasite strains are not isogenic, it is also possible that other genes
could exert an effect on the parasite response to MFQ. Studies in
which the expression from the additional pfmdr1 gene copies is
reduced or eliminated in Dd2 parasites would be useful in evalu-
ating the possibility of a threshold number of pfmdr1 gene copies
being necessary to cause the Dd2 MFQ-resistant phenotype.
Statistically significant upregulation of pfmdr1 following MFQ
treatment was observed in 3D7 and Dd2 parasites at the 12-hour
time point. Although the reason for this upregulation in 3D7 and
Dd2 but not FCB is unclear, subsequent analysis of parasite mor-
phology on the sampled cultures to correlate our pfmdr1 expres-
sion data with the parasite life cycle revealed an interesting phe-
notype. In agreement with a recent study that examined MFQ
exposure on synchronized rings only (36), our results revealed
that MFQ treatment of synchronized ring-stage parasites resulted
in a delay in parasite maturation at the ring stage of development.
When we analyzed the morphology of synchronized trophozoites,
we observed that MFQ exposure at the trophozoite stage also
FIG 5 Ring-stage-specific expression of pfmdr1 in untreated parasite strains
containing different pfmdr1 copy numbers. Untreated cultures of each parasite
strain were assessed for morphology (lines) and for pfmdr1 gene expression
(bars) relative to that of the P. falciparum lactate dehydrogenase gene. A direct
relationship between the proportion of ring-stage parasites in the culture and
the relative expression of pfmdr1 was observed.
TABLE 1 Half-maximal inhibitory concentration of artesunate in
parasite cultures before and after exposure to mefloquine
Parasite
strain
Mean IC50 (nM)  SD in:
Untreated cultures MFQ-treated culturesc
3D7a 0.61  0.04 0.62  0.07
Dd2b 0.39  0.05 0.40  0.02
a 3D7 parasites contain one pfmdr1 gene copy.
b Dd2 parasites contain four pfmdr1 gene copies.
c MFQ-treated cultures were exposed for 12 h to 100 ng/ml MFQ prior to IC50 analysis.
FIG 4 Morphology stage development of untreated and MFQ-treated syn-
chronized trophozoite parasites. Synchronized trophozoites of 3D7 (1 pfmdr1
copy), FCB (2 copies), and Dd2 (4 copies) parasites that were untreated or
mefloquine (MFQ) (100 ng/ml) treated were monitored over time. Untreated
cultures (top graph) progressed through the normal asexual cell cycle. MFQ
treatment caused a delay in parasite maturation at the ring stage (bottom
graph), resulting in a persistence of ring-stage parasites. All strains exhibited
this delay.
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caused the parasites to stall but only after the parasites matured
through the intraerythrocytic cycle to the ring stage. This indicates
that MFQ affected the parasites’ ability to proceed through the
asexual intraerythrocytic cycle only when ring-stage parasites
were exposed to the drug.
Two theories can explain the increase in pfmdr1 expression in
response to MFQ exposure: (i) direct induction of pfmdr1 gene
expression by MFQ or (ii) an indirect upregulation due to the
maturation delay. At each time point assessed, a direct relation-
ship between pfmdr1 expression levels and the proportion of ring-
stage parasites in the culture was observed. In one interval, be-
tween 12 and 24 h, the change in pfmdr1 expression was
consistently greater than the change in the proportion of ring-
stage parasites. This could be due to the difficulty in distinguishing
late rings and early trophozoites by light microscopy.
To demonstrate that MFQ-treated parasites were stalled at the
ring stage and were not dying parasites, we investigated the ex-
pression levels of the developmentally regulated trophozoite anti-
gen R45-like (tar45-like) gene, which is normally expressed in the
ring stage. Transcripts of the tar45-like gene also increased, peak-
ing at 12 h after the addition of MFQ. This increase was not ob-
served in untreated or atovaquone-treated cultures, which also
did not exhibit a maturation delay. Thus, the observed increases in
pfmdr1 transcript levels in the persistent rings found in MFQ-
treated cultures are likely due to an overall increase in the expres-
sion of ring-stage genes. Ring-stage-dependent transcription of
pfmdr1 would explain the apparent induction of expression after
treatment with a drug that slows the cell cycle at the ring stage.
Cell cycle delay upon drug exposure is a common phenome-
non, most often seen in cancer cells (37–40). Recently, such delays
have been described for P. falciparum treated with other drugs (34,
36, 41, 42). A drug-induced delay in parasite maturation through
the intraerythrocytic cycle was seen after short-term MFQ expo-
sure in MFQ-sensitive strains (36). Similarly, we showed that
treatment of synchronized ring-stage parasites with MFQ induced
a delay in parasite maturation in both the MFQ-sensitive (3D7
and FCB) and MFQ-resistant (Dd2) P. falciparum strains tested.
Our data revealed that this delay was only slightly altered in Dd2
parasites, which have four pfmdr1 copies. The MFQ-induced mat-
uration delay occurred as early as 6 h posttreatment, and the delay
was observed after MFQ treatment but not after ATQ treatment,
which indicates that it not a generalized response to the presence
of any antimalarial compound. Because decreased sensitivity to
other quinoline drugs has also been linked to elevated pfmdr1 copy
number, studies to evaluate the effects of other quinoline com-
pounds, such as quinine, on parasite maturation would be useful
to understand if this delay is due to a certain structural class of
antimalarial drugs.
There are two possible explanations for the observed effects of
MFQ on parasite maturation: (i) the presence of MFQ exerts an
effect on the parasites’ ability to progress through the asexual cell
cycle, or (ii) the maturation delay is an active response by the
parasite to adverse conditions caused by mefloquine. If the matu-
ration delay is caused by MFQ, then it would likely be a nonspe-
cific response, perhaps due to a disruption in the availability of
nutrients or energy for the parasite to be able to continue through
its normal asexual cycle. The addition of chemical agents that
inhibit protein synthesis, such as cycloheximide, for example,
could shed light on this as a possibility. However, if the maturation
delay is an active response by the parasite, one possible conse-
quence of the disruption in the parasite cell cycle is to allow time
for parasites to survive peak serum drug concentrations by pre-
venting the maturation to intraerythrocytic stages that express the
drug target. Such is the case for certain chemoresistant or radiore-
sistant phenotypes observed in cancer cells (43, 44). For example,
5-fluorouracil (5-FU) is a chemotherapeutic agent that specifi-
cally targets the S phase of the eukaryotic cell cycle. Cancer cells
resistant to 5-FU are known to arrest at the G1 phase following
5-FU exposure, thus preventing the drug from engaging its S-
phase target (43). These delays are directly linked to the treatment
dose and duration, and the removal of the therapy restores the
normal cell cycle. In P. falciparum, MFQ-induced cell cycle delay is
also dose dependent, and removal of MFQ drug pressure restores
cell cycle proliferation (36). This would explain the maturation
delay if MFQ activity is in one of the later intraerythrocytic stages.
A second explanation for the maturation delay and expression
increase could be that the delay is an initial response to the adverse
conditions caused by mefloquine but not by atovaquone. Parasites
could have evolved this delay mechanism to allow them to survive
a specific type of stress. All in all, further work is needed to under-
stand the etiology of this response.
Despite the rapid evolution of resistance to MFQ, its use has
gained new life in combination with artemisinin derivatives. Some
evidence suggests that the activity of artemisinin and its deriva-
tives is stage specific, with greater plasmocidal activity on late-
stage rings and trophozoites than on schizonts or early rings (45–
48), whereas other evidence indicates activity on all blood stages
(48–50). If the former is true, then MFQ should be additive or
synergistic with artesunate. On the other hand, elevated pfmdr1
copy numbers have been implicated as a cause of artesunate resis-
tance as well. Thus, if MFQ leads to increased pfmdr1 expression,
then it could be antagonistic with artesunate. Whereas our arte-
sunate IC50 values for 3D7 fell within the range of reported arte-
sunate sensitivity levels (3), our IC50 for Dd2 was slightly lower
than reported values. However, we found no differences in the
artesunate IC50 for untreated parasites compared with parasites of
the same strain that had been exposed to MFQ. This suggests that
(i) artesunate is neither synergistic nor antagonistic and (ii) the
effect of MFQ on parasite maturation does not alter its sensitivity
to artesunate. Thus, no evidence against combining artesunate
and mefloquine in malaria treatment was found.
An abundance of in vitro and clinical evidence links copy num-
ber increases in the P. falciparum multidrug resistance gene with
resistance to several antimalarial compounds (3, 12, 16, 20–22, 24,
25, 27). Our results on the maturation delay and the stage-depen-
dent transcription of pfmdr1 provide new insight into possible
resistance mechanisms mediated by copy number changes. The
slowing of the parasite intraerythrocytic cell cycle in response to
MFQ appears to be a general survival response by all P. falciparum
strains tested. This delay could function to alleviate time con-
straints by prolonging the ring stage, providing the opportunity
for higher production of drug transporter proteins in parasites
containing multiple pfmdr1 gene copies. This study was limited to
the investigation of pfmdr1. Experiments to explore the expression
of other important drug resistance transporter genes, such as pfcrt,
would be worthwhile. Additionally, further studies are needed to
fully understand the mechanism by which MFQ slows cell cycle
progression and whether this does increase the relative amount of
pfmdr1-encoded transporter expressed in each parasite. Particu-
larly, investigation into whether or not MFQ has an effect on cell
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cycle regulators, such as P. falciparum homologs for cyclin-depen-
dent kinases (51–57), would be worthwhile to determine if MFQ
delays maturation by interfering with one or more cell cycle en-
zymes.
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